GSE103567 EZH2 inhibition 5 v 3 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE103567_EZH2 inhibition_5_v_3_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE103567_EZH2 inhibition_5_v_3_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE103567_EZH2 inhibition_5_v_3_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE103567_EZH2 inhibition_5_v_3_human_up.

Results found

Linked to

 

Label

Description

 

Gene

H4 clustered histone 15

Gene

MSL complex subunit 3B

Gene

H2A clustered histone 19

Gene

CROCC pseudogene 2

Gene

H3.7 histone (putative)

Gene

long intergenic non-protein coding RNA 665

Gene

general transcription factor IIi pseudogene 4

Gene

small nucleolar RNA host gene 12

Gene

long intergenic non-protein coding RNA 3040

Gene

neutrophil cytosolic factor 1C (pseudogene)

  • Gene

    H4 clustered histone 15


  • Gene

    MSL complex subunit 3B


  • Gene

    H2A clustered histone 19


  • Gene

    CROCC pseudogene 2


  • Gene

    H3.7 histone (putative)


  • Gene

    long intergenic non-protein coding RNA 665


  • Gene

    general transcription factor IIi pseudogene 4


  • Gene

    small nucleolar RNA host gene 12


  • Gene

    long intergenic non-protein coding RNA 3040


  • Gene

    neutrophil cytosolic factor 1C (pseudogene)

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.